Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2023-03-06 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ENHERTU DESTINY-PANTUMOR02 SHOWS POSITIVE RESULTS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about positive clinical trial results for the drug Enhertu in the DESTINY-PanTumor02 Phase II trial. The document includes comprehensive data about the trial, drug approvals, and company information. It is not an annual or quarterly report, nor is it a simple announcement or certification. Form 6-K filings typically serve as current reports for foreign issuers to disclose material information. Given the detailed nature and the regulatory context, this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-06 English
Enhertu DESTINY-PanTumor02 shows positive results
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 9262R' and is dated '06 March 2023'. It contains a press release style announcement regarding clinical trial results ('Enhertu showed clinically meaningful and durable responses across multiple HER2-expressing tumour types in DESTINY-PanTumor02 Phase II trial'). The text concludes with standard disclaimers and contact information typical of an RNS (Regulatory News Service) release from the London Stock Exchange, including the final tag 'END RESFLFSAVAIEIIV'. This format strongly indicates a general regulatory announcement that does not fit the more specific categories like Earnings Release (ER) or Interim Report (IR). Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-03-06 English
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily includes an explanatory note about the issuance of fixed rate notes (debt securities) by AstraZeneca Finance LLC, guaranteed by AstraZeneca PLC. It includes exhibits such as underwriting agreements, pricing agreements, officers' certificates, and legal opinions related to the debt issuance. The document is relatively short (2664 characters) and serves as an announcement and incorporation of documents related to a financing transaction. There are no financial statements or detailed financial performance data presented. This fits the category of a Capital/Financing Update (CAP), as it provides updates on company fundraising and financing activities.
2023-03-03 English
Issuer Document
Capital/Financing Update Classification · 98% confidence The document is titled "Final Terms dated 1 March 2023" and details the specific terms for the "Issue of EUR 750,000,000 3.625 per cent. Notes due 2027 under the US$10,000,000,000 Euro Medium Term Note Programme." It explicitly states that this document constitutes the Final Terms and must be read in conjunction with the Base Prospectus. This structure—a document finalizing the terms of a specific debt issuance (Notes) under a pre-existing program—is characteristic of a prospectus supplement or final terms document related to capital raising or financing activities. Among the provided codes, 'Capital/Financing Update' (CAP) is the most appropriate fit for documenting the final terms of a new bond issuance, as opposed to a general regulatory filing (RNS) or a general report (10-K, IR).
2023-03-03 English
Issuer Document
Capital/Financing Update Classification · 98% confidence The document is titled 'Final Terms dated 1 March 2023' and details the specific terms for the 'Issue of EUR 750,000,000 3.750 per cent. Notes due 2032 under the US$10,000,000,000 Euro Medium Term Note Programme'. It explicitly states that these Final Terms must be read in conjunction with the Base Prospectus for the purposes of the UK Prospectus Regulation. This structure—a document finalizing the terms of a specific debt issuance (Notes) that references a base prospectus—is characteristic of documentation related to capital raising or financing activities, specifically bond issuance documentation. Reviewing the definitions, 'Capital/Financing Update (Code: CAP)' covers 'Updates on company fundraising, financing activities, or capital structure changes.' This document is the final pricing and terms sheet for a new debt issuance (Notes), which is a core financing activity. It is not a general earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), but a specific document detailing the terms of a capital raise.
2023-03-03 English
424B2
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(2) related to a debt securities offering by AstraZeneca Finance LLC, guaranteed by AstraZeneca PLC. It details the terms of the notes being offered, including interest rates, maturity dates, underwriting discounts, and other offering specifics. The document includes a prospectus supplement and an attached prospectus, which are typical for securities offerings. This type of document is an update on the company's capital raising activities through debt issuance, which fits the category of Capital/Financing Update filings. It is not an annual report, earnings release, or any other report type but specifically a financing prospectus supplement. The document length and content confirm it is not a mere announcement but a full prospectus supplement. Therefore, the correct classification is Capital/Financing Update (CAP).
2023-03-02 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.